Asthma - pathophysiology

Asthma is a chronic respiratory disease marked by airway inflammation, hyperresponsiveness, and reversible airflow obstruction. The pathophysiology involves a complex interplay of immune cells, inflammatory mediators, and structural changes, influenced by genetic and environmental factors, ultimately leading to symptoms like wheezing, shortness of breath, and coughing.

Note 1: Definition and Core Features of Asthma Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. This inflammation leads to airway narrowing, excessive mucus production, and constriction of the bronchial smooth muscle (bronchospasm). The resulting symptoms include wheezing, shortness of breath, chest tightness, and coughing, particularly at night or early morning. Asthma's severity varies greatly among individuals, from mild intermittent symptoms to severe persistent symptoms that significantly impact daily life. It's crucial to understand that asthma isn't simply 'tight airways'; the chronic inflammation is the primary driver of the disease, leading to structural changes in the airway over time (airway remodeling) if left uncontrolled. This remodeling can include thickening of the airway walls, increased smooth muscle mass, and increased mucus gland size. Understanding the chronic inflammatory nature is key to effective management.

Note 2: The Inflammatory Cascade in Asthma The inflammatory process in asthma involves a complex interaction of immune cells, including mast cells, eosinophils, T lymphocytes (particularly Th2 cells), and epithelial cells. Exposure to triggers (allergens, irritants, viral infections) initiates an immune response. Mast cells, sensitized by IgE antibodies, release inflammatory mediators such as histamine, leukotrienes, and prostaglandins upon encountering an allergen. These mediators cause bronchoconstriction, vasodilation, and increased vascular permeability, leading to edema and mucus secretion. Th2 cells release cytokines (IL-4, IL-5, IL-13) that promote IgE production, eosinophil activation, and mucus production. Eosinophils release toxic proteins that damage the airway epithelium, contributing to inflammation and hyperresponsiveness. This chronic inflammation, if untreated, can lead to airway remodeling and irreversible airflow obstruction.

Note 3: Bronchial Hyperresponsiveness (BHR) Bronchial hyperresponsiveness (BHR) is a hallmark feature of asthma. It refers to an exaggerated bronchoconstrictor response to various stimuli, such as allergens, irritants, cold air, and exercise. In individuals with asthma, even small amounts of these stimuli can trigger significant airway narrowing, leading to symptoms. The underlying mechanism involves increased sensitivity of the airway smooth muscle to constricting agents, as well as increased responsiveness due to structural changes in the airway wall. BHR is often assessed using bronchoprovocation tests, such as methacholine challenge tests, where increasing doses of methacholine are administered to induce bronchoconstriction. The degree of responsiveness is then measured by the decrease in forced expiratory volume in one second (FEV1). BHR is not unique to asthma but is more pronounced in asthmatics.

Note 4: Airway Remodeling in Chronic Asthma Chronic inflammation in asthma leads to structural changes in the airways, a process known as airway remodeling. These changes include: Sub-epithelial fibrosis (deposition of collagen beneath the airway epithelium); Smooth muscle hypertrophy and hyperplasia (increased size and number of smooth muscle cells); Angiogenesis (formation of new blood vessels); Increased mucus gland size and mucus production. Airway remodeling contributes to irreversible airflow obstruction and increased bronchial hyperresponsiveness, making asthma more difficult to control over time. Early and effective treatment of asthma, particularly with inhaled corticosteroids, can help to prevent or minimize airway remodeling. Once remodeling has occurred, it's often difficult to reverse, highlighting the importance of proactive asthma management.

Note 5: Genetic and Environmental Factors in Asthma Asthma is a complex disease influenced by both genetic and environmental factors. There isn't a single 'asthma gene,' but rather multiple genes that increase susceptibility to the disease. These genes are involved in immune regulation, airway inflammation, and bronchial hyperresponsiveness. Environmental factors play a crucial role in triggering asthma development and exacerbations. These factors include: Allergens (pollen, dust mites, pet dander, mold); Irritants (tobacco smoke, air pollution, chemicals); Viral respiratory infections; Occupational exposures. The interaction between genetic predisposition and environmental exposure determines an individual's risk of developing asthma. Identifying and avoiding triggers is an important part of asthma management.

Note 6: The Role of IgE in Allergic Asthma In allergic asthma, exposure to allergens triggers the production of allergen-specific IgE antibodies. These IgE antibodies bind to mast cells in the airways. Upon subsequent exposure to the same allergen, the allergen cross-links the IgE antibodies on the mast cell surface, causing the mast cell to degranulate and release inflammatory mediators. These mediators, such as histamine and leukotrienes, cause bronchoconstriction, vasodilation, and increased vascular permeability, leading to asthma symptoms. Anti-IgE therapy (omalizumab) is a targeted treatment option for patients with severe allergic asthma. It works by binding to IgE antibodies in the circulation, preventing them from binding to mast cells and reducing the release of inflammatory mediators.

Note 7: Asthma Phenotypes and Endotypes Asthma is not a single disease entity but rather a heterogeneous syndrome with different phenotypes (observable characteristics) and endotypes (underlying biological mechanisms). Phenotypes can be broadly classified based on age of onset (childhood vs. adult-onset), allergen sensitivity (allergic vs. non-allergic), and severity. Endotypes refer to the distinct molecular pathways and inflammatory profiles that drive asthma in different individuals. Identifying endotypes is a major focus of current asthma research, as it could lead to more targeted and personalized therapies. For example, some asthma endotypes are characterized by high levels of Th2 cytokines (IL-4, IL-5, IL-13), while others are driven by different inflammatory pathways.

Note 8: Clinical Manifestations and Diagnosis of Asthma The classic symptoms of asthma include wheezing, shortness of breath, chest tightness, and coughing. However, not all patients experience all of these symptoms, and symptom presentation can vary widely. Diagnosis is based on a combination of clinical history, physical examination, and lung function tests. Spirometry, which measures airflow, is the primary diagnostic tool. A significant improvement in FEV1 after bronchodilator administration (e.g., albuterol) supports the diagnosis of asthma. Peak expiratory flow (PEF) monitoring can also be used to assess airway obstruction. In some cases, bronchoprovocation testing (e.g., methacholine challenge) may be necessary to confirm the diagnosis. It is important to consider other conditions that can mimic asthma, such as COPD, vocal cord dysfunction, and upper airway obstruction.

Note 9: Exacerbations of Asthma: Pathophysiology and Management Asthma exacerbations are acute or subacute episodes of worsening asthma symptoms and decreased lung function. They are often triggered by viral respiratory infections, allergen exposure, or irritant exposure. The pathophysiology of exacerbations involves increased airway inflammation, bronchoconstriction, and mucus production, leading to severe airflow obstruction. Management of exacerbations typically involves: Increased doses of inhaled bronchodilators (e.g., albuterol); Systemic corticosteroids (oral or intravenous) to reduce inflammation; Oxygen therapy if needed. Severe exacerbations may require hospitalization and mechanical ventilation. Prevention of exacerbations is a key goal of asthma management, achieved through adherence to controller medications, avoidance of triggers, and prompt treatment of respiratory infections.

Note 10: Airway Inflammation and Mucus Production Inflammation of the airways is a central component of asthma pathophysiology. This inflammation leads to increased mucus production by goblet cells and submucosal glands. The mucus is often thicker and more viscous than normal, further contributing to airway obstruction. Inflammatory mediators such as histamine and leukotrienes stimulate mucus secretion. In addition, the damaged epithelium in asthmatic airways is less efficient at clearing mucus, leading to mucus plugging and airway obstruction. Certain medications, such as mucolytics, can help to break down mucus and facilitate its clearance, but their role in asthma management is limited.

Note 11: The role of the Nervous System The nervous system also plays a role in asthma. Both the parasympathetic and sympathetic nervous systems innervate the airways. Parasympathetic stimulation leads to bronchoconstriction and mucus secretion, while sympathetic stimulation leads to bronchodilation. In asthma, there is often an imbalance between these two systems, with increased parasympathetic tone contributing to bronchoconstriction. Beta-adrenergic agonists, such as albuterol, work by stimulating the sympathetic nervous system and causing bronchodilation. Anticholinergic medications, such as ipratropium bromide, block the parasympathetic nervous system and can also provide bronchodilation.

Note 12: Practical Implications and Future Directions Understanding the pathophysiology of asthma is crucial for effective diagnosis, treatment, and prevention. Current asthma management strategies focus on reducing airway inflammation, relieving bronchoconstriction, and preventing exacerbations. Future research is aimed at identifying novel therapeutic targets based on the underlying endotypes of asthma. This includes the development of personalized therapies that target specific inflammatory pathways or genetic predispositions. For patients it means a more personalised treatment plan tailored to their needs.

Browse public study notes